Neonatal intrahepatic cholestasis caused by citrin deficiency: severe hepatic dysfunction in an infant requiring liver transplantation

被引:87
作者
Tamamori, A
Okano, Y
Ozaki, H
Fujimoto, A
Kajiwara, M
Fukuda, K
Kobayashi, K
Saheki, T
Tagami, Y
Yamano, T
机构
[1] Osaka City Univ, Grad Sch Med, Dept Paediat, Abeno Ku, Osaka 5458585, Japan
[2] Fujidera City Hosp, Dept Paediat, Fujieda, Shizuoka, Japan
[3] Osaka City Gen Hosp, Dept Paediat, Osaka, Japan
[4] Osaka City Environm & Publ Hlth Assoc, Osaka, Japan
[5] Nara Med Univ, Dept Paediat, Kashihara, Nara, Japan
[6] Kagoshima Univ, Fac Med, Dept Biochem, Kagoshima, Japan
[7] Sapporo City Inst Publ Inst, Sapporo, Hokkaido, Japan
基金
日本学术振兴会;
关键词
argininosuccinate synthetase; cholestasis; citrin; citrullinaemia; liver transplantation;
D O I
10.1007/s00431-002-1045-2
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Adult-onset type 2 citrullinaemia (CTLN2) is caused by a deficiency of the citrin protein encoded by the SLC25A13 gene. Citrin, an aspartate glutamate carrier in mitochondria, is an essential component of the malate-aspartate NADH shuttle. Recently, citrin deficiency has been reported to manifest as neonatal intrahepatic cholestasis. We report here five cases with neonatal intrahepatic cholestasis caused by citrin deficiency. Genetic diagnosis revealed compound heterozygotes of 851del4/IVS11+1G-->A in two patients, IVS11+1G-->A/E601X, and IVS11+1G-->A/unknown in each one patient and homozygote for S225X in one patient. All cases revealed high levels of alpha-fetoprotein, which are not observed in CTLN2 patients. The condition was self-limiting and spontaneously disappeared after 5-7 months of age in four patients. However, one patient developed hepatic dysfunction from the age of 6 months and required a living-related liver transplantation at the age of 10 months. The patient showed complete recovery after transplantation, and now at the age of 3 years, shows normal growth and mental development. Conclusion: we report the first case of neonatal intrahepatic cholestasis caused by citrin deficiency with severe hepatic dysfunction requiring a living-related liver transplantation. Patients with this disorder should be followed up carefully, even during infancy.
引用
收藏
页码:609 / 613
页数:5
相关论文
共 23 条
[1]   Type II (adult onset) citrullinaemia: clinical pictures and the therapeutic effect of liver transplantation [J].
Ikeda, S ;
Yazaki, M ;
Takei, Y ;
Ikegami, T ;
Hashikura, Y ;
Kawasaki, S ;
Iwai, M ;
Kobayashi, K ;
Saheki, T .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 71 (05) :663-670
[2]  
Ishii A, 1992, Rinsho Shinkeigaku, V32, P853
[3]  
Kakinoki H, 1997, HUM MUTAT, V9, P250, DOI 10.1002/(SICI)1098-1004(1997)9:3<250::AID-HUMU6>3.3.CO
[4]  
2-K
[5]   TYPE-II CITRULLINEMIA ASSOCIATED WITH NEUTROPENIA [J].
KAMIYA, Y ;
HORIKOSHI, T ;
TAKAGI, H ;
OKADA, S ;
HASHIMOTO, K ;
KIDO, C ;
TAKEHARA, K ;
NAGAMINE, T ;
SEKIGUCHI, T ;
MORI, M .
INTERNAL MEDICINE, 1995, 34 (07) :679-682
[6]   Living-related liver transplantation for Type II citrullinemia using a graft from heterozygote donor [J].
Kasahara, M ;
Ohwada, S ;
Takeichi, T ;
Kaneko, H ;
Tomomasa, T ;
Morikawa, A ;
Yonemura, K ;
Asonuma, K ;
Tanaka, K ;
Kobayashi, K ;
Saheki, T ;
Takeyoshi, I ;
Morishita, Y .
TRANSPLANTATION, 2001, 71 (01) :157-159
[7]   Adult-onset type II citrullinemia: Clinical pictures before and after liver transplantation [J].
Kawata, A ;
Suda, M ;
Tanabe, H .
INTERNAL MEDICINE, 1997, 36 (06) :408-412
[8]   Pancreatic secretory trypsin inhibitor as a diagnostic marker for adult-onset type II citrullinemia [J].
Kobayashi, K ;
Horiuchi, M ;
Saheki, T .
HEPATOLOGY, 1997, 25 (05) :1160-1165
[9]   The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein [J].
Kobayashi, K ;
Sinasac, DS ;
Iijima, M ;
Boright, AP ;
Begum, L ;
Lee, JR ;
Yasuda, T ;
Ikeda, S ;
Hirano, R ;
Terazono, H ;
Crackower, MA ;
Kondo, I ;
Tsui, LC ;
Scherer, SW ;
Saheki, T .
NATURE GENETICS, 1999, 22 (02) :159-163
[10]  
Kobayashi K, 2000, CALCIUM: THE MOLECULAR BASIS OF CALCIUM ACTION IN BIOLOGY AND MEDICINE, P565